CAVIN4

Summary

CAVIN4 (caveolae associated protein 4, HGNC:33742) is a protein-coding gene on chromosome 9q31.1, encoding Caveolae-associated protein 4 (Q5BKX8). Modulates the morphology of formed caveolae in cardiomyocytes, but is not required for caveolar formation.

This gene encodes a protein containing two coiled-coil regions. The encoded protein promotes Rho/ROCK (Rho-kinase) signaling in cardiac muscles cells, and may facilitate myofibrillar organization.

Source: NCBI Gene 347273 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 125 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_001018116

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33742
Approved symbol	CAVIN4
Name	caveolae associated protein 4
Location	9q31.1
Locus type	gene with protein product
Status	Approved
Aliases	cavin-4
Ensembl gene	ENSG00000170681
Ensembl biotype	protein_coding
OMIM	617714
Entrez	347273

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000307584, ENST00000956994

RefSeq mRNA: 1 — MANE Select: NM_001018116 NM_001018116

CCDS: CCDS35083

Canonical transcript exons

ENST00000307584 — 2 exons

Exon	Start	End
ENSE00001163407	100578079	100578551
ENSE00001365530	100585765	100588389

Expression profiles

Bgee: expression breadth ubiquitous, 171 present calls, max score 98.84.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.8166 / max 247.8844, expressed in 122 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
97733	1.3961	106
97734	0.1951	47
97735	0.0857	27
97732	0.0692	27
97736	0.0562	23
97731	0.0143	10

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
quadriceps femoris	UBERON:0001377	98.84	gold quality
vastus lateralis	UBERON:0001379	98.82	gold quality
deltoid	UBERON:0001476	98.67	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.65	gold quality
tibialis anterior	UBERON:0001385	97.99	gold quality
biceps brachii	UBERON:0001507	97.86	gold quality
skeletal muscle tissue	UBERON:0001134	97.81	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	97.68	gold quality
left ventricle myocardium	UBERON:0006566	96.82	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.87	gold quality
body of tongue	UBERON:0011876	95.63	gold quality
skeletal muscle organ	UBERON:0014892	93.88	gold quality
gastrocnemius	UBERON:0001388	93.70	gold quality
muscle tissue	UBERON:0002385	93.44	gold quality
heart right ventricle	UBERON:0002080	93.05	gold quality
myocardium	UBERON:0002349	92.97	gold quality
muscle of leg	UBERON:0001383	92.69	gold quality
cardiac muscle of right atrium	UBERON:0003379	91.57	gold quality
heart left ventricle	UBERON:0002084	88.76	gold quality
cardiac ventricle	UBERON:0002082	88.74	gold quality
tongue	UBERON:0001723	87.87	gold quality
apex of heart	UBERON:0002098	85.79	gold quality
cardiac atrium	UBERON:0002081	84.84	gold quality
right atrium auricular region	UBERON:0006631	84.46	gold quality
heart	UBERON:0000948	83.87	gold quality
cortical plate	UBERON:0005343	78.50	gold quality
embryo	UBERON:0000922	76.94	gold quality
ganglionic eminence	UBERON:0004023	76.94	gold quality
superior surface of tongue	UBERON:0007371	75.82	gold quality
pharyngeal mucosa	UBERON:0000355	73.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.04

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

63 targeting CAVIN4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-221-3P	99.86	71.56	1329
HSA-MIR-222-3P	99.86	71.35	1337
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-1976	99.74	65.48	1127
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-4502	99.65	66.99	1021
HSA-MIR-3177-5P	99.65	70.38	1174
HSA-MIR-6516-3P	99.65	68.57	1238
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-3685	99.62	68.83	1621
HSA-MIR-510-3P	99.54	70.06	2965

Literature-anchored findings (GeneRIF, showing 3)

• MURC modulates RhoA signaling, and MURC plays an important role in the development of cardiac dysfunction and conduction disturbance with increased vulnerability to atrial arrhythmias. (PMID:18332105)
• MURC mutations impart loss-of-function effects on MURC functions and probably are causal variants in human dilated cardiomyopathy (PMID:21642240)
• MURC/cavin-4, especially in combination with Cav-3, may play a consistent role in the differentiation process of rhabdomyosarcoma. (PMID:26086601)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cavin4a	ENSDARG00000038658
danio_rerio	cavin4b	ENSDARG00000056743
mus_musculus	Cavin4	ENSMUSG00000028348
rattus_norvegicus	Cavin4	ENSRNOG00000008027

Paralogs (3): CAVIN2 (ENSG00000168497), CAVIN3 (ENSG00000170955), CAVIN1 (ENSG00000177469)

Protein

Protein identifiers

Caveolae-associated protein 4 — Q5BKX8 (reviewed: Q5BKX8)

Alternative names: Muscle-related coiled-coil protein, Muscle-restricted coiled-coil protein

All UniProt accessions (1): Q5BKX8

UniProt curated annotations — full annotation on UniProt →

Function. Modulates the morphology of formed caveolae in cardiomyocytes, but is not required for caveolar formation. Facilitates the recruitment of MAPK1/3 to caveolae within cardiomyocytes and regulates alpha-1 adrenergic receptor-induced hypertrophic responses in cardiomyocytes through MAPK1/3 activation. Contributes to proper membrane localization and stabilization of caveolin-3 (CAV3) in cardiomyocytes. Induces RHOA activation and activates NPPA transcription and myofibrillar organization through the Rho/ROCK signaling pathway.

Subunit / interactions. Component of the CAVIN complex composed of CAVIN1, CAVIN2, CAVIN3 and CAVIN4. Interacts with CAVIN1, ADRA1A and ADRA1B. Interacts with CAVIN2; this augments the transactivation of NPPA. Interacts with CAV3. Interacts with MAPK1 and MAPK3.

Subcellular location. Cytoplasm. Myofibril. Sarcomere. Cytosol. Cell membrane. Sarcolemma. Membrane. Caveola.

Domain organisation. The coiled coil domain (residues 44-77) is essential for membrane-targeting in cardiomyocytes.

Similarity. Belongs to the CAVIN family.

RefSeq proteins (1): NP_001018126* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026752	Cavin_fam	Family

Pfam: PF15237

UniProt features (13 total): modified residue 5, region of interest 3, coiled-coil region 2, chain 1, sequence conflict 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5BKX8-F1	66.21	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 336, 355, 172, 173, 326

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 74 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, GOCC_I_BAND, GOCC_PLASMA_MEMBRANE_REGION, GOCC_SARCOLEMMA, GOCC_PLASMA_MEMBRANE_RAFT, GSE13762_CTRL_VS_125_VITAMIND_DAY12_DC_DN, GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, DELACROIX_RARG_BOUND_MEF, GOCC_CAVEOLA, GOCC_SUPRAMOLECULAR_COMPLEX, GSE13522_WT_VS_IFNG_KO_SKIN_UP, GOCC_SUPRAMOLECULAR_POLYMER, GSE14415_NATURAL_TREG_VS_FOXP3_KO_NATURAL_TREG_UP, CHEMELLO_SOLEUS_VS_EDL_MYOFIBERS_UP

GO Biological Process (4): muscle organ development (GO:0007517), regulation of gene expression (GO:0010468), cell differentiation (GO:0030154), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (9): cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), caveola (GO:0005901), sarcoplasm (GO:0016528), Z disc (GO:0030018), sarcolemma (GO:0042383), membrane (GO:0016020), sarcomere (GO:0030017)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
cytoplasm	2
animal organ development	1
muscle structure development	1
gene expression	1
regulation of macromolecule biosynthetic process	1
cellular developmental process	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
plasma membrane raft	1
I band	1
plasma membrane	1
myofibril	1

Protein interactions and networks

STRING

632 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CAVIN4	CAVIN2	O95810	822
CAVIN4	CAV1	Q03135	663
CAVIN4	CAVIN1	Q6NZI2	661
CAVIN4	CAV3	P56539	645
CAVIN4	CAVIN3	Q969G5	579
CAVIN4	TRIM54	Q9BYV2	574
CAVIN4	RHOA	P06749	514
CAVIN4	CAV2	P51636	490
CAVIN4	BIN1	O00499	455
CAVIN4	PACSIN2	Q9UNF0	423
CAVIN4	EHD2	Q9NZN4	378
CAVIN4	STAC3	Q96MF2	377
CAVIN4	EHD3	Q9NZN3	370
CAVIN4	MYO18B	Q8IUG5	361
CAVIN4	MYOZ2	Q9NPC6	354

IntAct

12 interactions, top by confidence:

A	B	Type	Score
CAVIN4	NTAQ1	psi-mi:“MI:0915”(physical association)	0.560
CAVIN4	ZGPAT	psi-mi:“MI:0915”(physical association)	0.560
BYSL	CAVIN4	psi-mi:“MI:0915”(physical association)	0.560
CAVIN4	XRCC6	psi-mi:“MI:0915”(physical association)	0.400
HMGA1	CAVIN4	psi-mi:“MI:0915”(physical association)	0.400
NTAQ1	CAVIN4	psi-mi:“MI:0915”(physical association)	0.000
ZGPAT	CAVIN4	psi-mi:“MI:0915”(physical association)	0.000
BYSL	CAVIN4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (8): MURC (Two-hybrid), MURC (Two-hybrid), ZGPAT (Two-hybrid), MURC (Proximity Label-MS), MURC (Proximity Label-MS), MURC (Affinity Capture-MS), MURC (Two-hybrid), APP (Reconstituted Complex)

ESM2 similar proteins: A0MZ67, A1L260, A2AMM0, A2VDA9, A4IGC3, A5PJI6, A9C3W3, B1PRL5, B9EKI3, O35711, O35867, O54724, O76878, O94876, O95810, P34609, P55326, P70302, P83093, P84903, P85125, Q0IIE0, Q13586, Q29EP6, Q32PN7, Q58CP9, Q5BKX8, Q5FWS6, Q63918, Q66H98, Q674X7, Q69ZS8, Q69ZZ6, Q6NZI2, Q6P0R8, Q6P402, Q7T019, Q8CJ96, Q8K2Q9, Q8MJK1

Diamond homologs: A1L260, A2AMM0, A2VDA9, A4FV37, A5PJI6, B1PRL5, O54724, O95810, P85125, Q5BKX8, Q63918, Q66H98, Q6NZI2, Q969G5, Q9Z1H9, Q91VJ2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

125 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	80
Likely benign	27
Benign	12

Top pathogenic / likely-pathogenic (0)

SpliceAI

172 predictions. Top by Δscore:

Variant	Effect	Δscore
9:100578550:AGGT:A	donor_loss	1.0000
9:100578552:G:GC	donor_loss	1.0000
9:100585760:TTCA:T	acceptor_loss	1.0000
9:100585763:A:AG	acceptor_gain	1.0000
9:100585763:A:AT	acceptor_loss	1.0000
9:100585763:AG:A	acceptor_gain	1.0000
9:100585764:G:GA	acceptor_gain	1.0000
9:100585764:GG:G	acceptor_gain	1.0000
9:100585764:GGA:G	acceptor_gain	1.0000
9:100585764:GGAGA:G	acceptor_gain	1.0000
9:100578543:A:AG	donor_gain	0.9900
9:100578552:G:GG	donor_gain	0.9900
9:100585761:TCAGG:T	acceptor_gain	0.9800
9:100585762:CAGG:C	acceptor_gain	0.9800
9:100585763:AGGA:A	acceptor_gain	0.9800
9:100585764:GGAG:G	acceptor_gain	0.9800
9:100581910:C:G	donor_gain	0.9700
9:100578550:AG:A	donor_gain	0.9600
9:100578551:GG:G	donor_gain	0.9600
9:100585763:AGGAG:A	acceptor_gain	0.9600
9:100585765:G:C	acceptor_gain	0.9600
9:100585762:CAGGA:C	acceptor_gain	0.9500
9:100578549:CAG:C	donor_gain	0.9200
9:100581869:A:T	donor_gain	0.8800
9:100578548:CCAGG:C	donor_gain	0.8700
9:100578550:AGG:A	donor_gain	0.8700
9:100581864:A:T	donor_gain	0.8700
9:100578549:CAGGT:C	donor_gain	0.8600
9:100578548:CCAG:C	donor_gain	0.8400
9:100578552:G:T	donor_gain	0.8400

AlphaMissense

2422 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:100578531:T:C	F130L	0.991
9:100578533:C:A	F130L	0.991
9:100578533:C:G	F130L	0.991
9:100578264:G:C	A41P	0.989
9:100578532:T:C	F130S	0.984
9:100578253:T:C	L37P	0.982
9:100585960:T:C	F202L	0.980
9:100585962:T:A	F202L	0.980
9:100585962:T:G	F202L	0.980
9:100585961:T:C	F202S	0.979
9:100578535:G:C	R131P	0.978
9:100578546:T:C	F135L	0.978
9:100578548:C:A	F135L	0.978
9:100578548:C:G	F135L	0.978
9:100578460:G:C	R106P	0.977
9:100578295:A:C	Q51P	0.974
9:100578253:T:A	L37Q	0.973
9:100578358:T:C	L72P	0.973
9:100578538:T:A	V132E	0.972
9:100578544:T:A	I134K	0.970
9:100578241:T:A	I33N	0.969
9:100586049:A:C	R231S	0.965
9:100586049:A:T	R231S	0.965
9:100585949:T:A	I198N	0.963
9:100585949:T:G	I198S	0.960
9:100578367:T:C	L75P	0.957
9:100578262:T:A	V40E	0.953
9:100586033:T:A	V226E	0.952
9:100578532:T:G	F130C	0.951
9:100585953:G:C	K199N	0.951

dbSNP variants (sampled 300 via entrez): RS1000531874 (9:100585454 G>T), RS1000954624 (9:100580437 C>G), RS1001179979 (9:100577833 A>G), RS1001206089 (9:100578088 C>T), RS1001719649 (9:100578571 C>A), RS1002332015 (9:100584804 C>T), RS1002566644 (9:100581812 C>T), RS1002720009 (9:100587738 C>A), RS1002751004 (9:100587978 A>C), RS1002949329 (9:100586909 A>C), RS1003365668 (9:100576804 T>C), RS1003975193 (9:100583211 C>T), RS1003988736 (9:100582592 C>T), RS1004193452 (9:100577043 G>T), RS1004890049 (9:100585552 A>C)

Disease associations

OMIM: gene MIM:617714 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): dilated cardiomyopathy (MONDO:0005021)

Orphanet (1): Dilated cardiomyopathy (Orphanet:217604)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001644	Dilated cardiomyopathy

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002359_7	Plasma amyloid beta peptide concentrations (ABx-42)	7.000000e-06
GCST004735_8	Epstein-Barr virus copy number in lymphoblastoid cell lines	9.000000e-06
GCST012228_387	Waist-hip index	4.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005660	plasma beta-amyloid 1-42 measurement
EFO:0007788	BMI-adjusted waist-hip ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Doxorubicin	decreases expression	3
Daunorubicin	decreases expression	2
Mitoxantrone	decreases expression	2
bisphenol A	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
potassium chromate(VI)	affects cotreatment, increases expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
2,7-dihydroxynaphthalene	decreases expression	1
abrine	increases expression	1
incobotulinumtoxinA	decreases expression	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Tretinoin	decreases expression	1
Triclosan	decreases expression	1
Okadaic Acid	increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

158 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00374465	PHASE4	UNKNOWN	Therapy With Verapamil or Carvedilol in Chronic Heart Failure
NCT01293903	PHASE4	COMPLETED	Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy
NCT01557140	PHASE4	COMPLETED	A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
NCT01917149	PHASE4	COMPLETED	Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
NCT02115581	PHASE4	COMPLETED	Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
NCT06236022	PHASE4	RECRUITING	The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
NCT00333827	PHASE3	COMPLETED	Cell Therapy In Dilated Cardiomyopathy
NCT00505154	PHASE3	COMPLETED	Effect of Rosuvastatin on Left Ventricular Remodeling
NCT01223703	PHASE3	COMPLETED	PUFAs and Left Ventricular Function in Heart Failure
NCT01583114	PHASE3	TERMINATED	PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors
NCT01914081	PHASE3	UNKNOWN	Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
NCT02989181	PHASE3	UNKNOWN	Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea
NCT03439514	PHASE3	TERMINATED	A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT05849766	PHASE3	COMPLETED	Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
NCT06250257	PHASE3	RECRUITING	Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
NCT00629018	PHASE2	COMPLETED	Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
NCT00629096	PHASE2	COMPLETED	Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy
NCT00765518	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
NCT00847964	PHASE2	COMPLETED	Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery
NCT01020968	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
NCT01302171	PHASE2	COMPLETED	Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy
NCT01350310	PHASE2	COMPLETED	Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy
NCT02133911	PHASE2	COMPLETED	A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
NCT03071653	PHASE2	SUSPENDED	Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study
NCT03572660	PHASE2	ACTIVE_NOT_RECRUITING	Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM
NCT03775070	PHASE2	COMPLETED	Simvastatin Therapy in Patients With Dilated Cardiomyopathy.
NCT04405804	PHASE2	UNKNOWN	Early Administration of Ivabradine in Children With Heart Failure
NCT05410873	PHASE2	COMPLETED	Examining the Effects of Mitochondrial Oxidative Stress in DCM
NCT06632834	PHASE2	RECRUITING	Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation
NCT00585546	PHASE1	TERMINATED	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
NCT02293603	PHASE1	UNKNOWN	Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)
NCT03062956	PHASE1	COMPLETED	A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
NCT03129568	PHASE1	COMPLETED	Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy
NCT04982081	PHASE1	UNKNOWN	Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
NCT06381466	PHASE1	TERMINATED	A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
NCT06464588	PHASE1	RECRUITING	A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
NCT06902896	PHASE1	COMPLETED	Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
NCT07137338	PHASE1	RECRUITING	A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07241104	PHASE1	RECRUITING	A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy